News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ASCEND Therapeutics, Inc. Presents Results Of Phase 2 Clinical Trial For Cyclic Breast Pain; Company's Transdermal 4-OHT Therapy Was Well Tolerated And Reduced Breast Pain In Clinical Trial


10/19/2005 5:10:14 PM

HERNDON, Va.--(BUSINESS WIRE)--May 11, 2005--ASCEND Therapeutics, a leading research and development company of pharmaceutical transdermal therapies for the treatment of chronic conditions, today announced that researchers presented findings regarding the company's 4-hydroxytamoxifen (4-OHT) gel during the 53rd Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) at the Moscone Center in San Francisco. A poster presentation at ACOG offered data on the safety and efficacy of ASCEND Therapeutics' 4-OHT gel in patients with menstrual-cycle related mastalgia. The Phase 2 study, which was a placebo-controlled, double-blind, dose-ranging, and randomized study, indicated that the investigational transdermal 4-OHT gel, if approved by the FDA, may represent a new way to treat cyclic breast pain, also called cyclic mastalgia.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES